Published in Medical Letter on the CDC and FDA, April 26th, 2006
The Phase I study was designed to determine the safety and tolerability of Anthim in healthy volunteers, when administered with or without the antibiotic Ciprofloxacin.
The principal investigator for this study, Glen Apseloff, MD, Division of Clinical Pharmacology at The Ohio State University Clinical Pharmacology Unit commented, "The Anthim Phase 1 study, AH-101, has concluded and all subjects have completed the 42 day study. There were no serious adverse events and the drug was well tolerated,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA